[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-heart-failure":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,81,103,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100641302","fapl-imaging-assessment-of-revascularization-outcome-in-ischemic-heart-failure-100641302",false,"NCT07657650","FAPl Imaging Assessment of Revascularization Outcome in Ischemic Heart Failure","FARO","Inclusion Criteria:\n\n① Age ≥ 18 years; ② Meet the above-mentioned IHF diagnostic criteria; ③ Coronary angiography shows suitability for revascularization (PCI or CABG); ④ NYHA cardiac function classification is II-IV; ⑤ Sign the informed consent form.\n\nExclusion Criteria:\n\n① Heart failure caused by non-ischemic etiologies (such as dilated cardiomyopathy, valvular heart disease, myocarditis, etc.); ② Acute myocardial infarction occurred within the last 3 months; ③ Expected lifespan \\\u003C 1 year; ④ Complicated with other severe systemic diseases; ⑤ Has a history of tumors; ⑥ Has any conditions that are unsuitable for revascularization (such as uncorrectable coagulation dysfunction, active bleeding, etc.)","ALL","18 Years",{"count":19,"type":20},122,"ESTIMATED","OBSERVATIONAL","Ischemic heart failure (IHF) is the final stage of coronary heart disease. Coronary revascularization is an important treatment method for IHF, but it has high perioperative risks and not all patients can benefit from it. Evaluation of viable myocardium is one of the important decision-making methods for IHF, but recent research results have raised doubts about its value. The clinical community urgently needs more precise and comprehensive non-invasive decision-making methods. Fibroblast activation protein inhibitor (FAPI) imaging can specifically identify activated fibroblasts and achieve non-invasive diagnosis of the early and reversible stage of myocardial injury. Previous studies have shown that FAPI imaging can identify more damaged myocardium in various heart diseases compared to existing imaging techniques, demonstrating good clinical application potential. This study aims to conduct a prospective cohort trial for IHF patients who have undergone revascularization, using 18F-FAPI and viable myocardium (18F-FDG) imaging to analyze the degree of improvement in left ventricular ejection fraction after revascularization and major adverse cardiovascular events, and to explore the independent or additive predictive value of 18F-FAPI imaging, in order to provide a more reliable non-invasive imaging decision-making method for the revascularization strategy of IHF patients.",[24],"Ischemic Heart Failure",[26,27,28,29],"Ischemic heart failure","Revascularization","Fibroblast activation","Molecular imaging","RECRUITING","2026-07-01",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":34},"2026-04-10",{"date":38,"type":20},"2028-12-31",{"name":40,"class":41},"Beijing Chao Yang Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":42},"100643103","phase-1-hicm-188-cell-therapy-in-adults-with-advanced-heart-failure-undergoing-heart-bypass-surgery-100643103","NCT07646210","HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery","A Phase I\u002FIIa, Open-Label, Dose Escalation Study to Evaluate the Safety and Tolerability of HiCM-188, an Allogeneic iPSC-derived Cardiomyocyte Therapy, in Adult Patients With Advanced Heart Failure","Inclusion Criteria:\n\n* Able to sign informed consent and comply with the study protocol\n* 18 to 75 years old at the time of signing informed consent\n* Advanced heart failure patients with New York Heart Association (NYHA) class III to IVa despite receiving guideline-directed medical therapy (GDMT)\n* Patients with an indication for coronary artery bypass grafting (CABG) per 2011 ACCF\u002FAHA Guideline meeting a Class of Recommendation (COR) of Class I or Class IIa\n* Minimum left ventricular wall thickness of ≥ 8 mm in the areas of injection, as confirmed on the screening echocardiogram (ECHO) or cardiac MRI\n* Left ventricular ejection fraction (LVEF) of 20% to 45%, as confirmed on the screening echocardiogram (ECHO) or cardiac MRI\n* Other criteria apply. Please contact the investigator for more information.\n\nExclusion Criteria:\n\n* Viral myocarditis\n* Amyloidosis\n* Pericardial disorders or pericarditis\n* Left ventricular aneurysm or thrombus, except a small laminar thrombus at the site of previous myocardial infarction (MI) in a different area\n* Primary significant organic valvular heart disease, with specified dimensions\n* Untreated congenital heart disease\n* Complete atrioventricular (AV) conduction block\n* History of left ventricular assist device surgery\n* Other criteria apply. Please contact the investigator for more information.","75 Years",{"count":52,"type":20},12,"INTERVENTIONAL",[55,56],"PHASE1","PHASE2","This clinical study will evaluate the safety and tolerability of HiCM-188, an investigational allogeneic induced pluripotent stem cell (iPSC)-derived cardiomyocyte therapy, in adults with advanced heart failure who are undergoing coronary artery bypass grafting (CABG) surgery.\n\nParticipants who meet the study eligibility criteria will receive a single dose intramyocardial injection of HiCM-188 during CABG surgery. The study will evaluate two dose levels of HiCM-188 using an open-label dose-escalation design. Participants will be followed for up to 12 months after treatment to monitor safety and preliminary signs of clinical effect.",[59,24],"Advanced Heart Failure",[61,62,63,64,26,65,66,67,68,69],"HiCM-188","iPSC-derived cardiomyocytes","Allogeneic cell therapy","Advanced heart failure","Intramyocardial injection","Coronary artery bypass grafting","CABG","Dose escalation","NYHA Class III-IVa","NOT_YET_RECRUITING","2026-06-25",{"date":73,"type":34},"2026-06-29",{"date":75,"type":20},"2026-09",{"date":77,"type":20},"2028-05",{"name":79,"class":80},"HELP Therapeutics Co., Ltd.","INDUSTRY",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":53,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":42},"100629209","phase-1-hipsc-cms-loaded-chitosan-patch-to-treat-severe-chronic-ischemic-heart-disease-100629209","NCT07471698","hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Induce Pluripotent Stem Cell-derived Cardiomyocytes(HiCM-188) -Loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease","Inclusion Criteria:\n\n1. Age between 18 and 80 years (inclusive).\n2. Willingness and ability to give written informed consent.\n3. Chronic left ventricular dysfunction classified as Stage D (refractory end-stage heart failure) according to ACC staging criteria.\n4. NYHA functional class III-IV despite optimized guideline-directed medical therapy for heart failure.\n5. Indication for coronary artery bypass grafting (CABG), meeting one of the following anatomical criteria:\n\n   5.1 Class I Indications :\n   1. Left ventricular dysfunction with significant left main coronary artery disease;\n   2. Left ventricular dysfunction with \"left main equivalent\" disease (i.e., ≥70% stenosis in proximal LAD or proximal LCx);\n   3. Left ventricular dysfunction with two- or three-vessel disease including proximal LAD stenosis.\n\n   5.2 Class IIa Indication : Left ventricular dysfunction with substantial viable, akinetic but revascularizable myocardium, not covered by above Class I anatomical criteria.\n6. Left ventricular ejection fraction (LVEF) ≤40% as measured by echocardiography or cardiac MRI within 6 months prior to enrollment (excluding measurements obtained within 1 month post-myocardial infarction).\n7. Echocardiographic evidence of regional wall motion abnormalities (hypokinesis, akinesis, or presence of ventricular aneurysm).\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria are ineligible for study participation:\n\n1. History of permanent pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device implantation.\n2. Severe valvular heart disease or prior prosthetic valve replacement.\n3. Prior percutaneous coronary intervention (PCI) with stent implantation.\n4. Chronic atrial fibrillation.\n5. History of sustained ventricular tachycardia or aborted sudden cardiac death.\n6. Baseline estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m².\n7. Hematocrit \\\u003C25%.\n8. Severe contrast media allergy (anaphylactic or life-threatening reaction history).\n9. Coagulation disorder (INR \\>1.5 without therapeutic anticoagulation, platelets \\\u003C50×10⁹\u002FL, or clinically significant bleeding diathesis).\n10. Known hypersensitivity to penicillin or streptomycin.\n11. Contraindication to undergoing cardiac MRI (e.g., incompatible implanted devices, severe claustrophobia unresponsive to premedication).\n12. History of solid organ or bone marrow transplantation.\n13. Active malignancy or history of cancer within the past 5 years (except non-melanoma skin cancer or carcinoma in situ).\n14. Life expectancy \\\u003C1 year due to non-cardiac conditions.\n15. Long-term systemic immunosuppressive therapy (e.g., corticosteroids, TNF-α inhibitors).\n16. Contraindications to immunosuppressive therapy (e.g., active infection, uncontrolled diabetes, peptic ulcer disease).\n17. Active infectious diseases: HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis (Treponema pallidum, TP).\n18. Currently participating in another interventional clinical trial.\n19. Pregnant or lactating women.","80 Years",{"count":90,"type":20},16,[55,56],"This is an exploratory study. A total of 16 patients meeting the inclusion and exclusion criteria and awaiting coronary artery bypass grafting (CABG) surgery will be enrolled. After providing informed consent, participants will be randomized 1:1 under double-blind conditions into two groups:\n\n1. CABG + HiCM-188-loaded chitosan patch group (patch size: 2×4 cm; containing 5 million cells per patch)\n2. CABG + blank chitosan patch group (identical in appearance but without HiCM-188 cells).\n\nDuring CABG surgery, investigators will apply two HiCM-188-loaded chitosan patches onto the epicardial surface over regions of hypokinetic myocardium. The total transplanted cell dose per patient in the treatment group is 1 × 10⁷ . In the control group, eight patients will undergo identical surgical procedures with application of chitosan patches without HiCM-188 cells.",[24,94],"CABG-patients","2026-03-10",{"date":97,"type":34},"2026-03-13",{"date":99,"type":20},"2026-10-20",{"date":101,"type":20},"2028-10-20",{"name":79,"class":80},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":53,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":5},"100535947","cardiamp-heart-failure-ii-trial-for-patients-with-ischemic-heart-failure-with-reduced-ejection-fraction-100535947","NCT06258447","CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction","Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients With Ischemic Heart Failure II Trial","Inclusion Criteria:\n\n* New York Heart Association (NYHA) Class II or III\n* Diagnosis of chronic ischemic left ventricular dysfunction secondary to myocardial infarction (MI) as described in the study protocol.\n* Left ventricular ejection fraction \\>20% and \\\u003C40%\n* On stable evidence-based medical and device therapy for ischemic etiology heart failure per the ACC\u002FAHA Heart Failure guidelines, for at least three (3) months prior to randomization.\n* NTproBNP level of \\>500 pg\u002Fml\n* Autologous cell analysis score consistent with study selection assessment\n\nExclusion Criteria:\n\n* Selected study criteria as defined in the study protocol indicating that patient is not an optimal candidate for cardiac catheterization or intramyocardial delivery of autologous bone marrow mononuclear cells.","21 Years","90 Years",{"count":113,"type":20},250,[115],"NA","Concentrated autologous bone marrow mononuclear cells (ABM MNC) contain potentially therapeutic cell factors and past studies support therapeutic benefit to patients with cardiac diseases of acute myocardial infarction, ischemia, and heart failure when utilized as this study is designed. The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy system in patients with ischemic heart failure. It is a prospective, multi-center, randomized, controlled, patient and evaluator-blinded study comparing treatment with the CardiAMP cell therapy system to a control procedure with diagnostic catheterization.",[24],"2026-02-05",{"date":120,"type":34},"2026-02-09",{"date":122,"type":34},"2024-08-01",{"date":124,"type":20},"2029-04-01",{"name":126,"class":80},"BioCardia, Inc.",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":88,"enrollmentInfo":136,"targetDuration":4,"studyType":53,"phases":138,"briefSummary":139,"conditions":140,"keywords":144,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100619636","phase-1-endocardial-delivery-for-myocardial-regeneration-using-allogeneic-ipsc-derived-cardiomyocyte-spheroids-for-hf-with-systolic-dysfunction-emerald-study-100619636","NCT07347197","Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)","A Phase I\u002FII Study of Endocardial Delivery for Myocardial Regeneration Using Human Induced Pluripotent Stem (iPS) Cell-derived Cardiomyocyte Spheroids for Heart Failure Reduced Ejection Fraction","EMERALD","Inclusion Criteria:\n\n* Patients with resting left ventricular ejection fraction (LVEF) ≦40% based on institutional assessment on screening echocardiographic assessment\n* New York Heart Association (NYHA) cardiac function classification of grade II or III at screening\n* Other Criteria apply, please contact the investigator\n\nExclusion Criteria:\n\n* Patients with cardiac devices such as pacemakers, implantable cardioverter defibrillators (ICDs), or cardiac resuscitation-enabled implantable cardioverter defibrillators (CRT-Ds)\n* Patients with heart failure due to the primary disease hypertrophic cardiomyopathy (including the dilated phase), restrictive cardiomyopathy, amyloidosis, takotsubo cardiomyopathy, congenital heart disease, cardiac sarcoidosis, or constrictive pericarditis\n* Other Criteria apply, please contact the investigator","20 Years",{"count":137,"type":20},14,[55,56],"The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.",[141,24,142,143],"Heart Failure","Ischemic Heart Disease","Dilated Cardiomyopathy (DCM)",[141,26,142,143,145,146],"iPSC","cell therapy","2026-01-08",{"date":149,"type":34},"2026-01-16",{"date":151,"type":20},"2026-01-01",{"date":153,"type":20},"2030-01-31",{"name":155,"class":80},"Heartseed Inc."]